Key result
Sex-specific cTnT criteria identify a ~5-fold higher mild asymptomatic CTRCD incidence than sex-neutral cTnI.
Why the study?
The impact of recent ESC cardio-oncology guideline consensus definitions of cancer therapy-related cardiac dysfunction (CTRCD) on its reported incidence had not yet been assessed.
How do different biomarker criteria from the ESC Cardio-Oncology guidelines affect the reported incidence and prognostic value of cancer therapy-related cardiac dysfunction in breast cancer patients?
Population
118 patients participating in the PRADA trial
Comparison
Different asymptomatic CTRCD guideline criteria and alternative cTn 99th percentile URLs
Design
Retrospective analysis of trial participants
Follow-up
24 months (Q1-Q3: 21-29 months)
Authors
Loading...
Mild asymptomatic CTRCD predominates under ESC criteria; leaves open questions on surveillance intensity and prognostic impact.
Cohort (n=118)
How do different biomarker criteria from the ESC Cardio-Oncology guidelines affect the reported incidence and prognostic value of cancer therapy-related cardiac dysfunction in breast cancer patients?
Absolute Event Rate: 49.2% vs 9.3%
The reported incidence of mild asymptomatic cancer therapy-related cardiac dysfunction is highly dependent on the specific troponin assay and reference limits applied, and early elevation is not prognostic of long-term dysfunction.
Mecinaj et al. (2024) conducted a cohort in Breast cancer (adjuvant therapy) (n=118). Alternative cardiac troponin (cTn) 99th percentile upper reference limits (URLs) was evaluated on Cumulative incidence of mild asymptomatic CTRCD. The incidence of mild asymptomatic cancer therapy-related cardiac dysfunction varied markedly, ranging from 9.3% with sex-neutral cTnI to 49.2% with sex-specific cTnT criteria.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: